๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A novel disease-modifying osteoarthritis drug candidate targeting Runx1

โœ Scribed by Yano, F.; Hojo, H.; Ohba, S.; Fukai, A.; Hosaka, Y.; Ikeda, T.; Saito, T.; Hirata, M.; Chikuda, H.; Takato, T.; Kawaguchi, H.; Chung, U.-i.

Book ID
118744760
Publisher
BMJ Publishing Group
Year
2012
Tongue
English
Weight
780 KB
Volume
72
Category
Article
ISSN
0003-4967

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Regulation of B Cell Function by Lobenza
Regulation of B Cell Function by Lobenzarit, A Novel Disease-Modifying Antirheumatic Drug
โœ Shunsei Hirohata; Satoshi Shinohara; Tetsufumi Inoue; Terumasa Miyamoto; Peter E ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 718 KB

Objective. Lobenzarit (disodium 4-chloro-2,2'iminodibenzoate [CCA]) is a novel disease-modifying drug for the treatment of rheumatoid arthritis (RA). Although its clinical efficacy has been demonstrated, its mechanism of action remains unclear. We therefore examined the effects of CCA on in vitro Ig